Compare PRLB & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRLB | STOK |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2011 | 2019 |
| Metric | PRLB | STOK |
|---|---|---|
| Price | $79.64 | $31.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $53.00 | $39.20 |
| AVG Volume (30 Days) | 205.6K | ★ 609.8K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.33 | ★ 92.73 |
| EPS | ★ 0.33 | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | $8.56 | N/A |
| Revenue Next Year | $6.89 | $77.49 |
| P/E Ratio | $246.12 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $38.48 | $11.19 |
| 52 Week High | $83.15 | $40.22 |
| Indicator | PRLB | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 59.54 | 55.20 |
| Support Level | $52.62 | $30.34 |
| Resistance Level | $83.15 | $35.11 |
| Average True Range (ATR) | 2.98 | 1.54 |
| MACD | -0.09 | 0.28 |
| Stochastic Oscillator | 65.02 | 73.88 |
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. The Lab uses injection molding, computer numerical control machining, and 3-D printing, and sheet metal to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.